Group Leader/s

Head of lab


Our research group seeks to delve into the cellular and molecular bases of pulmonary vascular dysfunction, the gateway to the body for a multitude of agents capable of compromising people's health. Our research places a special focus on understanding endothelial damage and its connection with vascular smooth muscle and the immune system, all of which are very present in the development of cardiovascular diseases. We go from rare or infrequent diseases such as pulmonary arterial hypertension to other cardiopulmonary disorders resulting from exposure to various environmental factors, such as hypoxia, certain pollutants, drugs or respiratory infections. All these cardiopulmonary diseases affect both the lung vasculature and the heart in one way or another. The ultimate goal of our research is to find new targets, biomarkers and therapeutic strategies that contribute, from basic biology and experimental pharmacology, to solving the health challenges of our society.

pulmonary vascular disease



Santamans,A.M., Cicuendez, B., Mora, A., Villalba-Orero, M., Rajlic, S., Crespo, M., Vo, P., Jerome, M., Macias, A., Lopez, J.A., Leiva, M., Rocha, S.F., Leon, M., Rodriguez, E., Leiva, L., Pinto-Chocano, A., Garcia-Lunar, I., Garcia-Alvarez, A., Hernansanz-Agustin, P., Peinado, V.I., Barrera, J.A., Ibanez, B., Vazquez, J., Spinelli, J.B., Daiber, A., Oliver, E., Sabio, G.  [2024]. MCJ: A mitochondrial target for cardiac intervention in pulmonary hypertension. Sciences Advances, 10, eadk6524.



Funded by Ministerio de Ciencia e Innovación / Agencia Estatal de Investigación (PID2021-123167OB-I00, CEX2021-001226-S-20-8, PRE2022-104403 and RED2022-134299-T); by CSIC (Talent Attraction program 20222AT010 and Intramural 202420E038), by Comunidad de Madrid (PIPF-2022/SAL-GL-24824) and by La Marató de TV3 Foundation (202336-31).

pid csic




More info


Oliver E, Zhao L, Wilkins MR, and Aitman T. PCT/GB2016/052297. ZIP12 as a Therapeutic/Screening Candidate for Hypoxia-Induced Pulmonary Hypertension WO/2017/017446. Priority: UK (extended to world-wide application), Date: 28/07/2015. Status: entered into national phases in EP and US. Holder: Imperial Innovations Ltd.

Sánchez‐Sancho, F.; Csáky, A. G.; del Pozo, C; del Pozo, J.; Marcilla, A.; Ibázez Cabeza, B.; Oliver, E. Cumella, J. M.; Roscales, S. P202330530, N/Ref.: 2022_82 ES. Imidazo[1,2-a]pyridine derivatives with anti-inflammatory activity. Priority: España. Fecha: 27/06/2023. Status: Solicitada. Holders: Universitat de València, Consejo Superior de Investigaciones Científicas, Universidad Complutense de Madrid, Centro Nacional de Investigaciones Cardiovasculares Carlos III.

Honors and Awards 

  • Tenured Scientist. 2024-
  • I3 Certificate. 2023
  • Ramón y Cajal Fellow. Agencia Estatal de Investigación (RYC2020-028884-I) 2022-2024
  • ‘Prismas’ Honorific mention to the singular project modality for the initiative #CienciaenelParlamento. Museos Científicos Coruñeses. 2019
  • SRUK Mentoring recognition award. SRUK/CERU. 2018
  • Talent Atraction Senior Fellow (mod.1). Comunidad Autónoma de Madrid. 2018-2022
  • 1st Prize in Biological and Biomedical Sciences for Tutors. 16th ARQUIMEDES University Contest. Ministry of Education, Culture and Sports. 2017
  • Winner of the 32nd SEF Young Investigator Award to best career under 35 years old. Spanish Society of Pharmacology (SEF). 2017
  • Winner of the EPHAR Young Investigator Award. The Federation of European Pharmacological Societies (EPHAR). 2016
  • International Postdoctoral CNIC Fellow. Marie Sklodowska-Curie COFUND. 2016-2018
  • Expert on expatriate scientific networks. 'Los 100 de Cotec', Fundacion Cotec. 2016-2023
  • FPU Phd Fellow. Ministry of Science and Education. 2005-2009


RECENT NEWS about the group, click here.

*We are looking for candidates to do a Master and/or PhD with us! If you are interested in joining our group, send an e-mail to Eduardo including your CV and a motivation letter.


We are part of:

cibeercv renim nanomed
diamond rst